The Cost Effectiveness Analysis of PD-1 And PD-L1 Agents Compared with Docetaxel for Second-Line Treatment of Advanced Non-Small Cell Lung Cancer

Autor:	YH Bae-Shaaw, JW Hay
Rok vydání:	2018
Předmět:	Oncology medicine.medical_specialty Second line treatment biology business.industry Health Policy Public Health Environmental and Occupational Health Cost-effectiveness analysis medicine.disease Docetaxel PD-L1 Internal medicine medicine biology.protein Non small cell Lung cancer business medicine.drug
Zdroj:	Value in Health. 21:S30
ISSN:	1098-3015
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::329470a54ca9d2ce847086fa7d302ddf https://doi.org/10.1016/j.jval.2018.04.191 Zobrazit plný text záznamu Full Text from ScienceDirect